Kenneth Kintu

Summary

Publications

  1. pmc Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa
    Kenneth Kintu
    Makerere University Johns Hopkins University Research Collaboration, Kampala, Uganda
    J Acquir Immune Defic Syndr 63:1-8. 2013
  2. pmc Mentorship needs at academic institutions in resource-limited settings: a survey at Makerere University College of Health Sciences
    Damalie Nakanjako
    Department of Medicine, Makerere University College of Health Sciences, P, O, Box 7072, Kampala, Uganda
    BMC Med Educ 11:53. 2011
  3. doi request reprint Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa
    Pontiano Kaleebu
    Medical Research Council Uganda Virus Research Institute, Entebbe, Uganda SCHARP, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA Viral and Rickettsial Disease Laboratory, Richmond, CA Joint Clinical Research Center, Kampala, Uganda Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD Makerere University Johns Hopkins University Research Collaboration, Kampala, Uganda Department of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda George Washington University School of Public Health and Health Services, Washington, DC FHI 360, Durham, NC and Sanofi Pasteur, Discovery Drive, Swiftwater, PA
    J Acquir Immune Defic Syndr 65:268-77. 2014

Collaborators

Detail Information

Publications3

  1. pmc Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa
    Kenneth Kintu
    Makerere University Johns Hopkins University Research Collaboration, Kampala, Uganda
    J Acquir Immune Defic Syndr 63:1-8. 2013
    ..Safety and feasibility results from phase 1, randomized, double-blind, placebo-controlled trial of ALVAC-HIV vCP1521 in infants born to HIV type 1-infected women in Uganda are reported...
  2. pmc Mentorship needs at academic institutions in resource-limited settings: a survey at Makerere University College of Health Sciences
    Damalie Nakanjako
    Department of Medicine, Makerere University College of Health Sciences, P, O, Box 7072, Kampala, Uganda
    BMC Med Educ 11:53. 2011
    ..However, mentoring efforts are challenged by the high clinical, research and administrative demands. We evaluated the status and nature of mentoring practices at Makerere University College of Health Sciences (MAKCHS)...
  3. doi request reprint Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa
    Pontiano Kaleebu
    Medical Research Council Uganda Virus Research Institute, Entebbe, Uganda SCHARP, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA Viral and Rickettsial Disease Laboratory, Richmond, CA Joint Clinical Research Center, Kampala, Uganda Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD Makerere University Johns Hopkins University Research Collaboration, Kampala, Uganda Department of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda George Washington University School of Public Health and Health Services, Washington, DC FHI 360, Durham, NC and Sanofi Pasteur, Discovery Drive, Swiftwater, PA
    J Acquir Immune Defic Syndr 65:268-77. 2014
    ..Testing protective HIV-1 vaccines remains a critical priority. The immunogenicity of ALVAC-HIV vCP1521 (ALVAC) in infants born to HIV-1-infected women in Uganda was evaluated in the first pediatric HIV-1 vaccine study in Africa...